Time Points in the Assessment of MRD
" width="560">Transcript:Mark R. Litzow, MD: Anthony, when do you think we should be measuring MRD?
Anthony S. Stein, MD: I think it also depends which regimen you
EP: 1.Molecular Cytogenetic Risk Stratification in ALL
EP: 2.Pediatric-Inspired Regimens in ALL
EP: 3.How Age Affects Treatment Approaches in ALL
EP: 4.Effective Novel Agents in Upfront Treatment of ALL
EP: 5.Considerations of Cytoreduction in ALL
EP: 6.Revolutionizing the Treatment of Ph+ ALL with TKIs
EP: 7.Therapeutic Approaches in Philadelphia-like ALL
EP: 8.Role of MRD Testing in Adult Acute Lymphocytic Leukemia
Now Viewing
EP: 9.Time Points in the Assessment of MRD
EP: 10.Monitoring for Relapse in Acute Lymphoblastic Leukemia
EP: 11.Blinatumomab for Patients with MRD-Positive ALL
EP: 12.The Evolving Role of Transplant in ALL
EP: 13.CAR T: Dominant Therapy for B-Cell ALL
EP: 14.Examining the Toxicities of CAR T-cell Therapy
EP: 15.Acute Lymphocytic Leukemia: What's Next
EP: 16.Approaching the Management of Philadelphia-Negative ALL
EP: 17.Treatment Algorithms for Philadelphia-Negative ALL
EP: 18.Ph-Negative ALL: Establishing Blinatumomab's Role in Therapy
EP: 19.Blinatumomab: Safety Data in Ph-Negative ALL
EP: 20.Establishing MRD's Role in ALL Management
EP: 21.Allogeneic Transplant at First Remission of ALL
EP: 22.Selecting a Novel Therapy for Relapsed/Refractory ALL
EP: 23.When to Use Inotuzumab Ozogamicin for Adult ALL
EP: 24.Evaluating CAR T Therapy in Acute Lymphoblastic Leukemia
EP: 25.Future Treatment Strategies in Adult ALL
Related Videos
Related Content
